272.59 USD
-2.64 (-0.96%)
272.59 USD
0 (0%)
CME gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 235 industry peers in the Capital Markets industry. While CME belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. CME is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year CME was profitable.
- In the past year CME had a positive cash flow from operations.
- CME had positive earnings in each of the past 5 years.
- Each year in the past 5 years CME had a positive operating cash flow.
1.2 Ratios
- Looking at the Return On Assets, with a value of 1.99%, CME is in line with its industry, outperforming 45.96% of the companies in the same industry.
- The Return On Equity of CME (13.18%) is better than 72.77% of its industry peers.
- Looking at the Return On Invested Capital, with a value of 18.72%, CME belongs to the top of the industry, outperforming 95.74% of the companies in the same industry.
- CME had an Average Return On Invested Capital over the past 3 years of 15.81%. This is significantly above the industry average of 7.16%.
- The 3 year average ROIC (15.81%) for CME is below the current ROIC(18.72%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.99% | ||
| ROE | 13.18% | ||
| ROIC | 18.72% |
ROA(3y)2.17%
ROA(5y)1.91%
ROE(3y)11.65%
ROE(5y)10.5%
ROIC(3y)15.81%
ROIC(5y)11.95%
1.3 Margins
- With a decent Profit Margin value of 32.91%, CME is doing good in the industry, outperforming 79.57% of the companies in the same industry.
- CME's Profit Margin has declined in the last couple of years.
- The Operating Margin of CME (80.16%) is better than 98.72% of its industry peers.
- In the last couple of years the Operating Margin of CME has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 80.16% | ||
| PM (TTM) | 32.91% | ||
| GM | N/A |
OM growth 3Y9.92%
OM growth 5Y6.02%
PM growth 3Y-13.33%
PM growth 5Y-2.37%
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- Compared to 1 year ago, CME has about the same amount of shares outstanding.
- CME has more shares outstanding than it did 5 years ago.
- CME has a better debt/assets ratio than last year.
2.2 Solvency
- The Debt to FCF ratio of CME is 0.84, which is an excellent value as it means it would take CME, only 0.84 years of fcf income to pay off all of its debts.
- CME's Debt to FCF ratio of 0.84 is amongst the best of the industry. CME outperforms 89.36% of its industry peers.
- A Debt/Equity ratio of 0.12 indicates that CME is not too dependend on debt financing.
- CME's Debt to Equity ratio of 0.12 is fine compared to the rest of the industry. CME outperforms 79.15% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.84 | ||
| Altman-Z | N/A |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- CME has a Current Ratio of 1.02. This is a normal value and indicates that CME is financially healthy and should not expect problems in meeting its short term obligations.
- The Current ratio of CME (1.02) is comparable to the rest of the industry.
- CME has a Quick Ratio of 1.02. This is a normal value and indicates that CME is financially healthy and should not expect problems in meeting its short term obligations.
- CME has a Quick ratio (1.02) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.02 |
3. Growth
3.1 Past
- CME shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.41%, which is quite good.
- Measured over the past years, CME shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.57% on average per year.
- Looking at the last year, CME shows a quite strong growth in Revenue. The Revenue has grown by 10.03% in the last year.
- The Revenue has been growing by 13.14% on average over the past years. This is quite good.
EPS 1Y (TTM)8.41%
EPS 3Y15.32%
EPS 5Y8.57%
EPS Q2Q%0%
Revenue 1Y (TTM)10.03%
Revenue growth 3Y26.89%
Revenue growth 5Y13.14%
Sales Q2Q%-2.95%
3.2 Future
- Based on estimates for the next years, CME will show a small growth in Earnings Per Share. The EPS will grow by 7.92% on average per year.
- Based on estimates for the next years, CME will show a small growth in Revenue. The Revenue will grow by 4.71% on average per year.
EPS Next Y9.98%
EPS Next 2Y7.13%
EPS Next 3Y6.89%
EPS Next 5Y7.92%
Revenue Next Year6.33%
Revenue Next 2Y5.53%
Revenue Next 3Y5.51%
Revenue Next 5Y4.71%
3.3 Evolution
- The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 24.87 indicates a rather expensive valuation of CME.
- 62.55% of the companies in the same industry are cheaper than CME, based on the Price/Earnings ratio.
- CME's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.54.
- Based on the Price/Forward Earnings ratio of 23.15, the valuation of CME can be described as rather expensive.
- CME's Price/Forward Earnings ratio is in line with the industry average.
- CME is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 24.31, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.87 | ||
| Fwd PE | 23.15 |
4.2 Price Multiples
- 87.66% of the companies in the same industry are more expensive than CME, based on the Enterprise Value to EBITDA ratio.
- Based on the Price/Free Cash Flow ratio, CME is valued a bit cheaper than 60.85% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.07 | ||
| EV/EBITDA | 10.55 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- The decent profitability rating of CME may justify a higher PE ratio.
PEG (NY)2.49
PEG (5Y)2.9
EPS Next 2Y7.13%
EPS Next 3Y6.89%
5. Dividend
5.1 Amount
- CME has a Yearly Dividend Yield of 1.88%. Purely for dividend investing, there may be better candidates out there.
- CME's Dividend Yield is comparable with the industry average which is at 6.19.
- CME's Dividend Yield is comparable with the S&P500 average which is at 1.92.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.88% |
5.2 History
- The dividend of CME is nicely growing with an annual growth rate of 16.00%!
- CME has paid a dividend for at least 10 years, which is a reliable track record.
- CME has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)16%
Div Incr Years11
Div Non Decr Years11
5.3 Sustainability
- 104.85% of the earnings are spent on dividend by CME. This is not a sustainable payout ratio.
- CME's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP104.85%
EPS Next 2Y7.13%
EPS Next 3Y6.89%
272.59
-2.64 (-0.96%)
Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)10-22 2025-10-22/bmo
Earnings (Next)02-04 2026-02-04/amc
Inst Owners91.62%
Inst Owner Change-0.14%
Ins Owners0.24%
Ins Owner Change-0.44%
Market Cap98.30B
Revenue(TTM)11.29B
Net Income(TTM)3.72B
Analysts70
Price Target291.65 (6.99%)
Short Float %1.72%
Short Ratio3.31
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.88% |
Yearly Dividend9.97
Dividend Growth(5Y)16%
DP104.85%
Div Incr Years11
Div Non Decr Years11
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)0.59%
Min EPS beat(2)0.43%
Max EPS beat(2)0.76%
EPS beat(4)3
Avg EPS beat(4)0.49%
Min EPS beat(4)-1.28%
Max EPS beat(4)2.05%
EPS beat(8)6
Avg EPS beat(8)0.72%
EPS beat(12)10
Avg EPS beat(12)0.95%
EPS beat(16)14
Avg EPS beat(16)1.13%
Revenue beat(2)0
Avg Revenue beat(2)-0.83%
Min Revenue beat(2)-1.11%
Max Revenue beat(2)-0.54%
Revenue beat(4)0
Avg Revenue beat(4)-0.98%
Min Revenue beat(4)-1.72%
Max Revenue beat(4)-0.54%
Revenue beat(8)0
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)7.34%
Revenue beat(16)7
Avg Revenue beat(16)10.88%
PT rev (1m)0.89%
PT rev (3m)-0.19%
EPS NQ rev (1m)1.33%
EPS NQ rev (3m)1.16%
EPS NY rev (1m)0.47%
EPS NY rev (3m)0.11%
Revenue NQ rev (1m)1.36%
Revenue NQ rev (3m)1.3%
Revenue NY rev (1m)0.37%
Revenue NY rev (3m)0.08%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.87 | ||
| Fwd PE | 23.15 | ||
| P/S | 8.7 | ||
| P/FCF | 24.07 | ||
| P/OCF | 23.62 | ||
| P/B | 3.49 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.55 |
EPS(TTM)10.96
EY4.02%
EPS(NY)11.77
Fwd EY4.32%
FCF(TTM)11.33
FCFY4.15%
OCF(TTM)11.54
OCFY4.23%
SpS31.32
BVpS78.18
TBVpS-6.01
PEG (NY)2.49
PEG (5Y)2.9
Graham Number138.85
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.99% | ||
| ROE | 13.18% | ||
| ROCE | 24.11% | ||
| ROIC | 18.72% | ||
| ROICexc | 20.09% | ||
| ROICexgc | 151.85% | ||
| OM | 80.16% | ||
| PM (TTM) | 32.91% | ||
| GM | N/A | ||
| FCFM | 36.16% |
ROA(3y)2.17%
ROA(5y)1.91%
ROE(3y)11.65%
ROE(5y)10.5%
ROIC(3y)15.81%
ROIC(5y)11.95%
ROICexc(3y)17.24%
ROICexc(5y)12.98%
ROICexgc(3y)263.94%
ROICexgc(5y)202.43%
ROCE(3y)20.37%
ROCE(5y)15.39%
ROICexgc growth 3Y53.64%
ROICexgc growth 5Y25.03%
ROICexc growth 3Y41.34%
ROICexc growth 5Y22.06%
OM growth 3Y9.92%
OM growth 5Y6.02%
PM growth 3Y-13.33%
PM growth 5Y-2.37%
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.12 | ||
| Debt/FCF | 0.84 | ||
| Debt/EBITDA | 0.36 | ||
| Cap/Depr | 23.26% | ||
| Cap/Sales | 0.68% | ||
| Interest Coverage | 66.76 | ||
| Cash Conversion | 44.34% | ||
| Profit Quality | 109.88% | ||
| Current Ratio | 1.02 | ||
| Quick Ratio | 1.02 | ||
| Altman-Z | N/A |
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)24.77%
Cap/Depr(5y)29.97%
Cap/Sales(3y)0.96%
Cap/Sales(5y)1.86%
Profit Quality(3y)106.99%
Profit Quality(5y)105.5%
High Growth Momentum
Growth
EPS 1Y (TTM)8.41%
EPS 3Y15.32%
EPS 5Y8.57%
EPS Q2Q%0%
EPS Next Y9.98%
EPS Next 2Y7.13%
EPS Next 3Y6.89%
EPS Next 5Y7.92%
Revenue 1Y (TTM)10.03%
Revenue growth 3Y26.89%
Revenue growth 5Y13.14%
Sales Q2Q%-2.95%
Revenue Next Year6.33%
Revenue Next 2Y5.53%
Revenue Next 3Y5.51%
Revenue Next 5Y4.71%
EBIT growth 1Y12.23%
EBIT growth 3Y39.48%
EBIT growth 5Y19.95%
EBIT Next Year12.32%
EBIT Next 3Y7.91%
EBIT Next 5Y7.1%
FCF growth 1Y23.34%
FCF growth 3Y16.49%
FCF growth 5Y8.18%
OCF growth 1Y22.71%
OCF growth 3Y15.38%
OCF growth 5Y6.67%
CME GROUP INC / CME FAQ
What is the ChartMill fundamental rating of CME GROUP INC (CME) stock?
ChartMill assigns a fundamental rating of 5 / 10 to CME.
What is the valuation status of CME GROUP INC (CME) stock?
ChartMill assigns a valuation rating of 3 / 10 to CME GROUP INC (CME). This can be considered as Overvalued.
Can you provide the profitability details for CME GROUP INC?
CME GROUP INC (CME) has a profitability rating of 7 / 10.
What is the earnings growth outlook for CME GROUP INC?
The Earnings per Share (EPS) of CME GROUP INC (CME) is expected to grow by 9.98% in the next year.
Can you provide the dividend sustainability for CME stock?
The dividend rating of CME GROUP INC (CME) is 5 / 10 and the dividend payout ratio is 104.85%.